A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (APOLLO)

This study has been terminated.
(Terminated early in agreement with Health Authorities for feasibility reasons)
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01259297
First received: December 10, 2010
Last updated: February 27, 2014
Last verified: February 2014

December 10, 2010
February 27, 2014
January 2011
November 2012   (final data collection date for primary outcome measure)
  • Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen [ Time Frame: End of study (209 days (median)) ] [ Designated as safety issue: No ]
    The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
  • Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group [ Time Frame: End of study (209 days (median)) ] [ Designated as safety issue: No ]
    The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure
Reduction in risk of major cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke and significant heart failure) [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01259297 on ClinicalTrials.gov Archive Site
  • Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I) [ Time Frame: Baseline, End of study (209 days [median]) ] [ Designated as safety issue: No ]

    Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:

    • Community Cognition (maximum of scores of questions 1 to 6);
    • Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);
    • Mobility (maximum of scores of questions 11 and 12);.
    • Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.
  • Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II) [ Time Frame: End of study (209 days [median]) ] [ Designated as safety issue: No ]

    Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).

    Part II of SAGE included 2 dimensions:

    • "Normal" if the scores of all SAGE questions is 0 (i.e., No difficulty)
    • "Mobility Only" if scores of both SAGE questions 11 and 12 are 0
  • Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen [ Time Frame: End of study (209 days (median)) ] [ Designated as safety issue: No ]

    The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:

    • End-stage renal disease [ESRD] requiring dialysis or transplantation
    • Doubling of serum creatinine and reaching an eGFR < 45 ml/min/1.73 m^2.
  • Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen [ Time Frame: End of study (209 days (median)) ] [ Designated as safety issue: Yes ]
    The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.
  • Prevention of decline in the ability to perform everyday activities independently [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
  • Prevention of decline in renal function. [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
  • Reduction of total mortality [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) [ Time Frame: Baseline (BL), 6 week, 6 month and 12 month ] [ Designated as safety issue: No ]
    Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
  • Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) [ Time Frame: Baseline (BL), 6 week, 6 month and 12 month ] [ Designated as safety issue: No ]
    Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.
Not Provided
 
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global measures of physical, executive and cognitive function.

This was 2x2 factorial design study with 2 strata. As per protocol, the first co- Primary analysis as well as secondary analysis were aliskiren based regimen vs non-aliskiren based regimen. All aliskiren based arm were combined into the aliskiren based regimen and all non-aliskiren based arms were combined into non-aliskiren based regimen.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cardiovascular Events
  • Drug: Aliskiren
    Aliskiren 150/300 mg once daily
  • Drug: Amlodipine
    Amlodipine 5 mg
  • Drug: Hydrochlorothiazide (HCTZ)
    HCTZ 12.5/25 mg
  • Drug: Placebo for Aliskiren
    Placebo for Aliskiren 300 mg
  • Drug: Placebo for Amlodipine
    Placebo for Amlodipine
  • Drug: Placebo for Hydrochlorothiazide (HCTZ)
    Placebo for HCTZ 12.5/25 mg
  • Experimental: Aliskiren + Amlodipine

    In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.

    In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.

    Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.

    Interventions:
    • Drug: Aliskiren
    • Drug: Amlodipine
  • Experimental: Aliskiren + Hydrochlorothiazide (HCTZ)

    In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.

    In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.

    Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.

    Interventions:
    • Drug: Aliskiren
    • Drug: Hydrochlorothiazide (HCTZ)
  • Experimental: Aliskiren + Placebo for Amlodipine

    In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.

    In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg

    Interventions:
    • Drug: Aliskiren
    • Drug: Placebo for Amlodipine
  • Experimental: Aliskiren + Placebo for HCTZ

    In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.

    In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily

    Interventions:
    • Drug: Aliskiren
    • Drug: Placebo for Hydrochlorothiazide (HCTZ)
  • Experimental: Amlodipine + Placebo for Aliskiren

    In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.

    In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily

    Interventions:
    • Drug: Amlodipine
    • Drug: Placebo for Aliskiren
  • Experimental: HCTZ + Placebo for Aliskiren

    In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.

    In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily

    Interventions:
    • Drug: Hydrochlorothiazide (HCTZ)
    • Drug: Placebo for Aliskiren
  • Placebo Comparator: Placebo for Aliskiren + Placebo for Amlodipine

    In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.

    In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily

    Interventions:
    • Drug: Placebo for Aliskiren
    • Drug: Placebo for Amlodipine
  • Placebo Comparator: Placebo for Aliskiren + Placebo for HCTZ

    In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.

    In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily

    Interventions:
    • Drug: Placebo for Aliskiren
    • Drug: Placebo for Hydrochlorothiazide (HCTZ)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
2336
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Systolic blood pressure 130 - 159 mmHg with any one of the following (1, 2 or 3):

  1. Men and women aged ≥ 65 years if they have at least one of the following: (secondary prevention) Coronary heart disease

    • Previous myocardial infarction or
    • Stable angina or unstable angina with documented multi-vessel coronary artery disease, > 50% stenosis in at least 2 major coronary arteries on coronary angiography, or positive stress test (ECG or nuclear perfusion scintogram), or
    • Multi-vessel PCI, or
    • Multi-vessel CABG surgery > 4 years prior to informed consent, or with recurrent angina or ischemia following surgery Stroke/TIA Previous documented stroke or documented TIA < 1 year before informed consent Peripheral artery disease
    • Previous limb bypass surgery or percutaneous transluminal angioplasty, or
    • Previous limb or foot amputation, or
    • History of intermittent claudication, with an ankle:arm BP ratio ≤ 0.80 on at least one side, or significant peripheral artery stenosis (> 50%) documented by angiography or non-invasive testing
    • Diabetes mellitus: High-risk diabetics with evidence of end-organ damage
  2. Men and women aged ≥ 65 years with no history of CVD, and with at least 1 CV risk factor (primary prevention):

    • History of dyslipidemia, defined as LDL cholesterol > 3.5 mmol/L (135 mg/dL) or HDL< 1.3 mmol/L (50 mg/dL) in women or < 1.0 mmol/L (39 mg/dL) in men or total cholesterol/HDL ratio > 5
    • History of current or recent smoking (regular tobacco use within 5 years)
    • Abdominal adiposity defined as waist/hip ratio ≥ 0.90 in women and ≥ 0.95 in men
    • History of dysglycemia defined as impaired fasting glucose (IFG - fasting plasma glucose 5.6 to 6.9 mmol/L [101 to 124 mg/dL]), or impaired glucose tolerance (IGT - fasting plasma glucose < 7 mmol/L [126 mg/dL] but 2 hour glucose 7.8 to 11.0 mmol/L [140 to 198 mg/dL]) or type 2 diabetes
    • Renal dysfunction: eGFR< 60 ml/min/1.73m2 but > 30 ml/min/1.73m2 (MDRD formula) and/or microalbuminurea/macroalbuminurea
    • Clinical evidence of left ventricular hypertrophy
  3. Men and women aged ≥ 70 years if they do not have any of the above (primary prevention)

Exclusion Criteria:

  1. Current treatment with aliskiren, an ACE-inhibitor, an ARB or an aldosterone antagonist and unable to discontinue this therapy in those without clinical vascular disease. Individuals with CVD or type 2 diabetes and/or renal dysfunction may receive an ACE-inhibitor or an ARB, but not both, contraindications to Aliskiren, Amlodipine or Hydrochlorothiazide.
  2. Use of both thiazide diuretic and amlodipine or another calcium channel blocker. Patients on only one of these two classes of drugs are eligible
  3. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
  4. Symptomatic heart failure, requiring the use of loop diuretics
  5. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve). Constrictive pericarditis. Complex congenital heart disease.
  6. Acute stroke < 3 months or TIA ≤ 7 days before informed consent, acute coronary syndrome < 1 months before informed consent
  7. Planned cardiac surgery or angioplasty < 3 months after informed consent or having had the procedure < 3 months before informed consent
  8. Severe renal impairment eGFR ≤ 30 ml/min/1.73m2 (MDRD formula); known renal artery stenosis ; serum potassium ≥ 5.3 mmol/L
  9. Chronic liver disease (i.e. cirrhosis, esophageal varices, portocaval shunt or persistent hepatitis) or abnormal liver function, i.e., alanine transaminase (ALT) or AST > 3x upper limit of normal (ULN)
  10. Concurrent treatment with cyclosporine or quinidine; chronic use of non-steroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX 2) inhibitors in patients with eGFR < 60 ml/min/1.73m2 (MDRD formula)
  11. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years regardless of whether there is evidence of local recurrence or metastases
  12. Other serious condition(s) likely to interfere with study participation or with the ability to complete the study. Significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the study procedures
Both
65 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Brazil,   Canada,   Chile,   Colombia,   Czech Republic,   Germany,   Hungary,   India,   Ireland,   Israel,   Malaysia,   Netherlands,   Philippines,   South Africa,   Spain,   Sweden
 
NCT01259297
CSPP100G2301, 2009-010170-38
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP